Rabies Immunoglobulin (Human)
KamRAB
- Dosage form
- Tablet
- Available strengths
- 150 IU/mL (2 mL and 10 mL vials)
- Drug class
- Passive immunizing agent (human rabies immunoglobulin)
- Common brand
- KamRAB
Clinical overview. Rabies immunoglobulin (brand name KamRAB) is a human plasma-derived antibody product used for immediate, short-term protection against rabies after a bite or scratch from an animal that may be rabid. It is given as a single weight-based dose, infiltrated around the wound and into muscle, together with the first dose of a full rabies vaccine series. It has no absolute contraindications given the near-uniformly fatal nature of untreated rabies, though it can cause injection site reactions and, rarely, allergic reactions.
Indication
Common therapeutic uses
- Rabies immunoglobulin is used for passive, short-term post-exposure protection against rabies after contact with an animal that is rabid or suspected of being rabid.
- Rabies immunoglobulin is given together with a full course of rabies vaccine, not on its own.
- Rabies immunoglobulin is not given to people who have already completed a full pre-exposure or post-exposure rabies vaccination series with confirmed adequate antibody levels.
Pregnancy
Risk assessment and monitoring considerations
- Rabies immunoglobulin has not been specifically studied in pregnant women, so the risk of birth defects or miscarriage with its use is unknown.
- Because rabies is almost always fatal once symptoms develop, post-exposure treatment, including rabies immunoglobulin, should not be withheld from a pregnant woman who has been exposed.
Breastfeeding
Infant exposure considerations
- There is no information on whether rabies immunoglobulin passes into breast milk or affects a breastfeeding infant; the clinical need for treatment after a rabies exposure should be weighed against any theoretical risk.
Geriatrics
Dosing and tolerability considerations
- Clinical studies did not include enough patients aged 65 and older to determine whether they respond differently, but clinical experience with human rabies immunoglobulin products has not shown differences in effectiveness between elderly and younger patients.
Pediatrics
Use in children and adolescents
- Rabies immunoglobulin has been studied in children as young as 6 months of age and is used in pediatric patients following the same weight-based dosing principle as in adults.
Dosage & Administration
Practical dosing and administration
- The recommended dose of rabies immunoglobulin is 20 IU per kilogram of body weight, given as a single dose at the time of the first rabies vaccine dose.
- Rabies immunoglobulin and the first vaccine dose should be given as soon as possible after exposure, but rabies immunoglobulin can still be given up to seven days after the first vaccine dose if there is a delay.
- As much of the dose as possible should be infiltrated into and around any visible bite wound, with any remaining volume given intramuscularly at a site away from the vaccine injection site.
- If the bite site is unknown or cannot be infiltrated, the full dose is given intramuscularly at a site distant from the vaccine.
- No more than the recommended dose should be given, and repeat doses should not be given once vaccination has started, because rabies immunoglobulin can partially block the body's own antibody response to the vaccine.
- Rabies immunoglobulin must not be mixed with the rabies vaccine or given in the same syringe or at the same injection site as the vaccine.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Giving more than the recommended dose of rabies immunoglobulin may partially suppress the body's own antibody response to the rabies vaccine, so doses above the recommended amount should be avoided.
- The product monograph does not describe a specific overdose toxidrome beyond this immune-interference effect; any symptoms that occur would be managed with supportive care.
Common side effects
Frequently reported tolerability concerns
- Pain at the injection site may occur.
- Headache may occur.
- Muscle pain may occur.
- Symptoms of an upper respiratory tract infection may occur.
- Joint pain may occur.
- Dizziness may occur.
- Fatigue may occur.
- Abdominal pain may occur.
- Blood detected in the urine may occur.
- Nausea may occur.
- Feeling faint may occur.
- Bruising at the injection site may occur.
- A sunburn-like skin reaction may occur.
- White blood cells detected on a urine test may occur.
- Fever is common in children receiving this product.
- Pain in the arm or leg used for injection is common in children.
- Redness or swelling at the injection site may occur, particularly in children.
- Mild vomiting may occur, particularly in children.
- Mouth or oral pain has been reported in children.
- Difficulty sleeping (insomnia) has been reported in children more than two weeks after administration.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Serious allergic reactions, including swelling of the face and throat, difficulty breathing, and rash, can occur and require immediate medical attention.
- Anaphylaxis can occur, particularly in patients with a prior severe reaction to other human immunoglobulin products or with isolated immunoglobulin A (IgA) deficiency.
- Because rabies immunoglobulin is made from pooled human plasma, there is a small possibility it could transmit an infectious agent, including unknown viruses, despite donor screening and viral inactivation steps.
- Fever, chills, and dark urine can occur and should be reported promptly.
- Bleeding complications can occur at the injection site in patients with bleeding disorders or low platelet counts.
- Wound complications at the injection or bite site have been reported in children.
- Seek urgent medical attention for swelling of the face or throat, difficulty breathing, a widespread rash, or fever with dark urine.
Use with caution
Situations requiring closer assessment
- Use with caution, by the subcutaneous route rather than intramuscular, in patients with uncorrectable bleeding disorders, although there is no clinical efficacy data supporting the subcutaneous route.
- Use with caution in patients with a history of severe allergic reactions to other human immunoglobulin products.
- Use with caution in patients with isolated immunoglobulin A (IgA) deficiency, who may be at greater risk of severe hypersensitivity reactions.
- Use with caution in patients who have recently received or are scheduled to receive a live attenuated virus vaccine, since rabies immunoglobulin can interfere with the vaccine's effectiveness.
- Use with caution in patients who have already completed a full rabies vaccination series, since rabies immunoglobulin is generally not needed and may blunt the booster response.
- Epinephrine should be available whenever rabies immunoglobulin is given, in case of an acute allergic reaction.
Contraindications
Situations where therapy may be inappropriate
- There are no absolute contraindications to rabies immunoglobulin, given the serious and typically fatal nature of untreated rabies exposure.
Drug interactions
Clinically relevant combinations
- Rabies immunoglobulin should not be given in the same syringe or at the same injection site as the rabies vaccine, since mixing them can reduce the vaccine's effectiveness.
- Repeat doses of rabies immunoglobulin should not be given after the vaccine series has started, since this can suppress the body's own antibody response.
- Immunization with live measles vaccine should be avoided for about 4 months after rabies immunoglobulin administration, since it can interfere with the vaccine's effectiveness.
- Immunization with other live attenuated virus vaccines, such as mumps or rubella, should be avoided for about 3 months after rabies immunoglobulin administration.
- Rabies immunoglobulin can cause temporary, misleading positive results on some blood antibody tests, including tests for red blood cell antibodies (Coombs' test).
Food interactions
Meal-related administration
- Not applicable; rabies immunoglobulin is given by injection under professional supervision, so food timing does not apply.
Time of administration
Practical scheduling
- Rabies immunoglobulin is given once, as soon as possible after a rabies exposure, at the same time as the first dose of rabies vaccine, by a healthcare professional; it is not a medicine a patient takes on their own schedule.
Storage
Product handling
- Store rabies immunoglobulin refrigerated at 2°C to 8°C and do not freeze; it may be kept at room temperature up to 25°C for up to one month, but once removed from refrigeration it should be used within that month and not placed back in the refrigerator.
Patient take-away
Key counselling points for a quick closing summary
- Rabies immunoglobulin gives immediate, short-term protection against rabies while the body builds its own immunity from the vaccine series.
- It is given as a single dose along with the first rabies vaccine dose, usually right after a bite or scratch from an animal that might have rabies.
- Seek emergency care immediately if you notice swelling of the face or throat, difficulty breathing, or a severe rash after receiving this treatment.
- Complete the full rabies vaccine series as scheduled, since rabies immunoglobulin alone does not provide lasting protection.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.